Gliatech hires outsider for corrective actions:
This article was originally published in Clinica
Gliatech has hired an external auditor for corrective actions and future filings to the FDA under the regulator's Application Integration Policy (AIP). Gliatech recalled its Adcon-L anti-adhesion gel in January following possible contamination and was placed on a special FDA AIP watch list following earlier post approval trials which were conducted unacceptably (see Clinica No 943 p 11).
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.